Journal
MOLECULES
Volume 25, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/molecules25020429
Keywords
BGP-15; chaperone co-inducer; PARP inhibitor; insulin sensitizer
Funding
- Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the Research and Development on Therapeutic Purposes Thematic Programme of the University of Debrecen [NKFIH-1150-6/2019]
- European Union
- European Social Fund
- Richter Gedeon Talent foundation
- [EFOP-3.6.1-16-2016-00022]
Ask authors/readers for more resources
BGP-15 is a new insulin sensitizer drug candidate, which was developed by Hungarian researchers. In recent years, numerous research groups have studied its beneficial effects. It is effective in the treatment of insulin resistance and it has protective effects in Duchenne muscular dystrophy, diastolic dysfunction, tachycardia, heart failure, and atrial fibrillation, and it can alleviate cardiotoxicity. BGP-15 exhibits chemoprotective properties in different cytostatic therapies, and has also proven to be photoprotective. It can additionally have advantageous effects in mitochondrial-stress-related diseases. Although the precise mechanism of the effect is still unknown to us, we know that the molecule is a PARP inhibitor, chaperone co-inducer, reduces ROS production, and is able to remodel the organization of cholesterol-rich membrane domains. In the following review, our aim was to summarize the investigated molecular mechanisms and pharmacological effects of this potential API. The main objective was to present the wide pharmacological potentials of this chemical agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available